

Marcel M Verbeek

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9400669/publications.pdf>

Version: 2024-02-01

278
papers

16,608
citations

13099

68
h-index

19190

118
g-index

326
all docs

326
docs citations

326
times ranked

18643
citing authors

#	ARTICLE	IF	CITATIONS
1	Prevalence of cerebral amyloid angiopathy: A systematic review and meta-analysis. <i>Alzheimer's and Dementia</i> , 2022, 18, 10-28.	0.8	93
2	Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 207-219.	2.3	44
3	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. <i>JAMA Neurology</i> , 2022, 79, 228.	9.0	97
4	Elevated expression of urokinase plasminogen activator in rodent models and patients with cerebral amyloid angiopathy. <i>Neuropathology and Applied Neurobiology</i> , 2022, 48, e12804.	3.2	0
5	Views on the Desirability of Diagnosing Sporadic Cerebral Amyloid Angiopathy with Biological Evidence. <i>Journal of Alzheimer's Disease</i> , 2022, , 1-10.	2.6	0
6	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. <i>Alzheimer's and Dementia</i> , 2022, 18, 1868-1879.	0.8	26
7	Normal cerebrospinal fluid concentrations of PDGFR ^{Î²} in patients with cerebral amyloid angiopathy and Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2022, 18, 1788-1796.	0.8	6
8	Inhibition of Neuroinflammation May Mediate the Disease-Modifying Effects of Exercise: Implications for Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2022, 12, 1419-1422.	2.8	2
9	Concordance of <i>CSF RT-QuIC</i> across the European <i>Creutzfeldt-Jakob</i> Disease surveillance network. <i>European Journal of Neurology</i> , 2022, , .	3.3	7
10	Mechanisms of peripheral levodopa resistance in Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2022, 8, 56.	5.3	29
11	The novel P330L pathogenic variant of aromatic amino acid decarboxylase maps on the catalytic flexible loop underlying its crucial role. <i>Cellular and Molecular Life Sciences</i> , 2022, 79, 305.	5.4	8
12	Serum GFAP differentiates Alzheimer's disease from frontotemporal dementia and predicts MCI-to-dementia conversion. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 659-667.	1.9	21
13	Factors associated with mortality in early stages of parkinsonism. <i>Npj Parkinson's Disease</i> , 2022, 8, .	5.3	4
14	CSF Î±-synuclein correlates with CSF neurogranin in late-life depression. <i>International Journal of Neuroscience</i> , 2021, 131, 357-361.	1.6	10
15	Novel Protein Biomarkers of Monoamine Metabolism Defects Correlate with Disease Severity. <i>Movement Disorders</i> , 2021, 36, 690-703.	3.9	7
16	Mapping the multicausality of Alzheimer's disease through group model building. <i>GeroScience</i> , 2021, 43, 829-843.	4.6	26
17	White Matter Hyperintensities Are No Major Confounder for Alzheimer's Disease Cerebrospinal Fluid Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 163-175.	2.6	5
18	Clinical presentation and long-term follow-up of dopamine beta hydroxylase deficiency. <i>Journal of Inherited Metabolic Disease</i> , 2021, 44, 554-565.	3.6	13

#	ARTICLE	IF	CITATIONS
19	Chitotriosidase as biomarker for early stage amyotrophic lateral sclerosis: a multicenter study. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2021, 22, 276-286.	1.7	14
20	Physiologically based pharmacokinetic/pharmacodynamic model for the prediction of morphine brain disposition and analgesia in adults and children. <i>PLoS Computational Biology</i> , 2021, 17, e1008786.	3.2	12
21	Peripheral decarboxylase inhibitors paradoxically induce aromatic L-amino acid decarboxylase. <i>Npj Parkinson's Disease</i> , 2021, 7, 29.	5.3	14
22	Human type 1 and type 2 conventional dendritic cells express indoleamine 2,3-dioxygenase 1 with functional effects on T cell priming. <i>European Journal of Immunology</i> , 2021, 51, 1494-1504.	2.9	11
23	Antisense Oligonucleotide-Induced Amyloid Precursor Protein Splicing Modulation as a Therapeutic Approach for Dutch-Type Cerebral Amyloid Angiopathy. <i>Nucleic Acid Therapeutics</i> , 2021, 31, 351-363.	3.6	8
24	Neurofilament light chain: A novel blood biomarker in patients with ataxia telangiectasia. <i>European Journal of Paediatric Neurology</i> , 2021, 32, 93-97.	1.6	7
25	Blood, urine and cerebrospinal fluid analysis in TH and AADC deficiency and the effect of treatment. <i>Molecular Genetics and Metabolism Reports</i> , 2021, 27, 100762.	1.1	3
26	Polyglutamine-Expanded Ataxin-3: A Target Engagement Marker for Spinocerebellar Ataxia Type 3 in Peripheral Blood. <i>Movement Disorders</i> , 2021, 36, 2675-2681.	3.9	22
27	Autoimmune Encephalitis Resembling Dementia Syndromes. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, .	6.0	22
28	Off-label use of aducanumab for cerebral amyloid angiopathy. <i>Lancet Neurology</i> , The, 2021, 20, 596-597.	10.2	17
29	Phase II trial of natalizumab for the treatment of anti-Hu associated paraneoplastic neurological syndromes. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab145.	0.7	3
30	MFG-E8 (LACTADHERIN): a novel marker associated with cerebral amyloid angiopathy. <i>Acta Neuropathologica Communications</i> , 2021, 9, 154.	5.2	11
31	Insights into the expanding phenotypic spectrum of inherited disorders of biogenic amines. <i>Nature Communications</i> , 2021, 12, 5529.	12.8	21
32	Cerebrospinal fluid levels of the neurotrophic factor neuroleukin are increased in early Alzheimer's disease, but not in cerebral amyloid angiopathy. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 160.	6.2	5
33	Identification of cerebrospinal fluid biomarkers for parkinsonism using a proteomics approach. <i>Npj Parkinson's Disease</i> , 2021, 7, 107.	5.3	11
34	Prevalence of sporadic cerebral amyloid angiopathy: A systematic review and meta-analysis. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	2
35	Amyloid-beta peptides in CSF and plasma discriminate cerebral amyloid angiopathy from controls. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	2
36	Urokinase plasminogen activator (uPA) as a novel biomarker for cerebral amyloid angiopathy. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.8	0

#	ARTICLE	IF	CITATIONS
37	Linking APOE- μ 4, blood-brain barrier dysfunction, and inflammation to Alzheimer's pathology. <i>Neurobiology of Aging</i> , 2020, 85, 96-103.	3.1	41
38	Reader response: Blood NfL: A biomarker for disease severity and progression in Parkinson disease. <i>Neurology</i> , 2020, 95, 657.2-658.	1.1	0
39	Cerebrospinal fluid monocyte chemoattractant protein 1 correlates with progression of Parkinson's disease. <i>Npj Parkinson's Disease</i> , 2020, 6, 21.	5.3	17
40	Metabolomics biomarker discovery in cerebrospinal fluid for cerebral amyloid angiopathy. <i>Alzheimer's and Dementia</i> , 2020, 16, e041934.	0.8	0
41	Urokinase plasminogen activator (uPA) as a novel biomarker for cerebral amyloid angiopathy. <i>Alzheimer's and Dementia</i> , 2020, 16, e042512.	0.8	0
42	Neuroleukin: A potential cerebrospinal fluid biomarker for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e042741.	0.8	0
43	Platelet-derived growth factor receptor-beta as a potential CSF biomarker for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e042924.	0.8	0
44	International initiative for harmonization of cerebrospinal fluid diagnostic comments in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e047209.	0.8	1
45	Confirmation of neurometabolic diagnoses using age-dependent cerebrospinal fluid metabolomic profiles. <i>Journal of Inherited Metabolic Disease</i> , 2020, 43, 1112-1120.	3.6	16
46	Consensus guideline for the diagnosis and treatment of tetrahydrobiopterin (BH4) deficiencies. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 126.	2.7	85
47	Cerebrospinal fluid myelin basic protein is elevated in multiple system atrophy. <i>Parkinsonism and Related Disorders</i> , 2020, 76, 80-84.	2.2	8
48	Proteomic profiling of striatal tissue of a rat model of Parkinson's disease after implantation of collagen-encapsulated human umbilical cord mesenchymal stem cells. <i>Journal of Tissue Engineering and Regenerative Medicine</i> , 2020, 14, 1077-1086.	2.7	4
49	CSF levels of glutamine synthetase and GFAP to explore astrocytic damage in seronegative NMOSD. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 605-611.	1.9	17
50	Disturbed balance in the expression of MMP9 and TIMP3 in cerebral amyloid angiopathy-related intracerebral haemorrhage. <i>Acta Neuropathologica Communications</i> , 2020, 8, 99.	5.2	17
51	Inflammation biomarker discovery in Parkinson's disease and atypical parkinsonisms. <i>BMC Neurology</i> , 2020, 20, 26.	1.8	51
52	Reduced Influence of apoE on A β 243 Aggregation and Reduced Vascular A β 243 Toxicity as Compared with A β 240 and A β 242. <i>Molecular Neurobiology</i> , 2020, 57, 2131-2141.	4.0	6
53	Sleep-Cognition Hypothesis In maritime Pilots, what is the effect of long-term work-related poor sleep on cognition and amyloid accumulation in healthy middle-aged maritime pilots: methodology of a case-control study. <i>BMJ Open</i> , 2019, 9, e026992.	1.9	9
54	A β 243 in human Alzheimer's disease: effects of active A β 242 immunization. <i>Acta Neuropathologica Communications</i> , 2019, 7, 141.	5.2	20

#	ARTICLE	IF	CITATIONS
55	Valuing biomarker diagnostics for dementia care: enhancing the reflection of patients, their care-givers and members of the wider public. <i>Medicine, Health Care and Philosophy</i> , 2019, 22, 439-451.	1.8	6
56	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology. <i>JAMA Neurology</i> , 2019, 76, 1035.	9.0	455
57	Serum NFL discriminates Parkinson disease from atypical parkinsonisms. <i>Neurology</i> , 2019, 92, e1479-e1486.	1.1	100
58	Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study. <i>Alzheimer's and Dementia</i> , 2019, 15, 742-753.	0.8	82
59	Î±-Synuclein real-time quaking-induced conversion in the cerebrospinal fluid of uncertain cases of parkinsonism. <i>Annals of Neurology</i> , 2019, 85, 777-781.	5.3	94
60	Cerebrospinal Fluid Galectin-1 Levels Discriminate Patients with Parkinsonism from Controls. <i>Molecular Neurobiology</i> , 2019, 56, 5067-5074.	4.0	7
61	Cerebral tryptophan metabolism and outcome of tuberculous meningitis: an observational cohort study. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 526-535.	9.1	77
62	Mutations in <i>CYB561</i> Causing a Novel Orthostatic Hypotension Syndrome. <i>Circulation Research</i> , 2018, 122, 846-854.	4.5	22
63	Biomarkers in cerebrospinal fluid for synucleinopathies, tauopathies, and other neurodegenerative disorders. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 146, 99-113.	1.8	5
64	White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 30.	6.2	40
65	Plasma AÎ² (Amyloid-Î²) Levels and Severity and Progression of Small Vessel Disease. <i>Stroke</i> , 2018, 49, 884-890.	2.0	27
66	Prevalence of the apolipoprotein E Îµ4 allele in amyloid Î² positive subjects across the spectrum of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 913-924.	0.8	58
67	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. <i>World Journal of Biological Psychiatry</i> , 2018, 19, 244-328.	2.6	215
68	Association of Cerebral Amyloid-Î² Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , 2018, 75, 84.	11.0	133
69	Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. <i>Neurology</i> , 2018, 90, e22-e30.	1.1	148
70	P3â€232: THE ASSOCIATION BETWEEN BLOODâ€BRAINâ€BARRIER DYSFUNCTION AND CSF Pâ€TAU IS MEDIATED BY BETAâ€AMYLOID IN THE PRESENCE OF ELEVATED ILâ€6. <i>Alzheimer's and Dementia</i> , 2018, 14, P1160.	0.8	0
71	P3â€246: Câ€REACTIVE PROTEIN, PLASMA AMYLOID BETA LEVELS AND MRI MARKERS: THE ROTTERDAM STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P1166.	0.8	1
72	O3â€09â€04: PLASMA AMYLOID Î² LEVELS, CEREBRAL ATROPHY AND DEMENTIA RISK: THE ROTTERDAM STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P1037.	0.8	0

#	ARTICLE	IF	CITATIONS
73	C-Reactive Protein, Plasma Amyloid- β^2 Levels, and Their Interaction With Magnetic Resonance Imaging Markers. <i>Stroke</i> , 2018, 49, 2692-2698.	2.0	46
74	Quantitative Genetics Validates Previous Genetic Variants and Identifies Novel Genetic Players Influencing Alzheimer's Disease Cerebrospinal Fluid Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 639-652.	2.6	12
75	The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review. <i>Alzheimer's and Dementia</i> , 2018, 14, 1313-1333.	0.8	87
76	Parkinson's Disease Diagnostic Observations (PADDO): study rationale and design of a prospective cohort study for early differentiation of parkinsonism. <i>BMC Neurology</i> , 2018, 18, 69.	1.8	7
77	Plasma amyloid- β^2 levels, cerebral atrophy and risk of dementia: a population-based study. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 63.	6.2	39
78	Consensus guideline for the diagnosis and treatment of aromatic l-amino acid decarboxylase (AADC) deficiency. <i>Orphanet Journal of Rare Diseases</i> , 2017, 12, 12.	2.7	172
79	Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 543-555.	2.6	10
80	Upstream SLC2A1 translation initiation causes GLUT1 deficiency syndrome. <i>European Journal of Human Genetics</i> , 2017, 25, 771-774.	2.8	15
81	β^2 -Amyloid in CSF. <i>Neurology</i> , 2017, 88, 169-176.	1.1	58
82	Animal models of cerebral amyloid angiopathy. <i>Clinical Science</i> , 2017, 131, 2469-2488.	4.3	43
83	Plasma Amyloid- β^2 Levels, Cerebral Small Vessel Disease, and Cognition: The Rotterdam Study. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 977-987.	2.6	43
84	The increasing impact of cerebral amyloid angiopathy: essential new insights for clinical practice. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 982-994.	1.9	162
85	Limitations of the hCMEC/D3 cell line as a model for A β^2 clearance by the human blood-brain barrier. <i>Journal of Neuroscience Research</i> , 2017, 95, 1513-1522.	2.9	52
86	MicroRNAs in Cerebrospinal Fluid as Potential Biomarkers for Parkinson's Disease and Multiple System Atrophy. <i>Molecular Neurobiology</i> , 2017, 54, 7736-7745.	4.0	119
87	Soluble TLR2 and 4 concentrations in cerebrospinal fluid in HIV/SIV-related neuropathological conditions. <i>Journal of NeuroVirology</i> , 2017, 23, 250-259.	2.1	9
88	[O2-04-06]: ASSOCIATION BETWEEN NOCTURNAL AMYLOID BETA FLUCTUATIONS AND SLEEP. <i>Alzheimer's and Dementia</i> , 2017, 13, P559.	0.8	0
89	[P4-394]: ASSOCIATIONS OF PLASMA AMYLOID BETA LEVELS WITH SEVERITY AND PROGRESSION OF CEREBRAL SMALL VESSEL DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P1479.	0.8	0
90	Multicenter Analytical Validation of A β^2 40 Immunoassays. <i>Frontiers in Neurology</i> , 2017, 8, 310.	2.4	10

#	ARTICLE	IF	CITATIONS
91	Regulator of oligodendrocyte maturation, miR-219, a potential biomarker for MS. <i>Journal of Neuroinflammation</i> , 2017, 14, 235.	7.2	41
92	Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 101.	6.2	43
93	Serum S100B: A proxy marker for grey and white matter status in the absence and presence of (increased risk of) psychotic disorder?. <i>PLoS ONE</i> , 2017, 12, e0174752.	2.5	2
94	Nigrosome-1 on Susceptibility Weighted Imaging to Differentiate Parkinson's Disease From Atypical Parkinsonism: An In Vivo and Ex Vivo Pilot Study. <i>Polski Przegląd Radiologii i Medycyny Nuklearnej</i> , 2016, 81, 363-369.	1.0	36
95	Validation of microRNAs in Cerebrospinal Fluid as Biomarkers for Different Forms of Dementia in a Multicenter Study. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 1321-1333.	2.6	44
96	White Matter Hyperintensities Potentiate Hippocampal Volume Reduction in Non-Demented Older Individuals with Abnormal Amyloid- β . <i>Journal of Alzheimer's Disease</i> , 2016, 55, 333-342.	2.6	16
97	Tau Rather than TDP-43 Proteins are Potential Cerebrospinal Fluid Biomarkers for Frontotemporal Lobar Degeneration Subtypes: A Pilot Study. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 585-595.	2.6	41
98	CSF d-serine concentrations are similar in Alzheimer's disease, other dementias, and elderly controls. <i>Neurobiology of Aging</i> , 2016, 42, 213-216.	3.1	40
99	Hourly analysis of cerebrospinal fluid glucose shows large diurnal fluctuations. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2016, 36, 899-902.	4.3	19
100	Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics. <i>Journal of Alzheimer's Disease</i> , 2016, 52, 51-64.	2.6	18
101	Validation of soluble amyloid- β precursor protein assays as diagnostic CSF biomarkers for neurodegenerative diseases. <i>Journal of Neurochemistry</i> , 2016, 137, 112-121.	3.9	17
102	Disease specificity of autoantibodies to cytosolic 5-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 696-701.	0.9	116
103	Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders. <i>Journal of Neurochemistry</i> , 2016, 139, 290-317.	3.9	58
104	The utility of α -synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature. <i>Biomarkers in Medicine</i> , 2016, 10, 19-34.	1.4	86
105	MicroRNA-29a Is a Candidate Biomarker for Alzheimer's Disease in Cell-Free Cerebrospinal Fluid. <i>Molecular Neurobiology</i> , 2016, 53, 2894-2899.	4.0	120
106	Amyloid- β Oligomers Relate to Cognitive Decline in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 45, 35-43.	2.6	52
107	Cerebrospinal Fluid NfCAM is not a Suitable Biomarker to Discriminate between Dementia Disorders – A Pilot Study. <i>Journal of Alzheimer's Disease</i> , 2015, 46, 605-609.	2.6	4
108	P4-229: Improved CSF-based discrimination between Alzheimer's disease patients and controls after correction for ventricular volumes. , 2015, 11, P868-P868.		0

#	ARTICLE	IF	CITATIONS
109	An integrated multi-study analysis of intra-subject variability in cerebrospinal fluid amyloid- β concentrations collected by lumbar puncture and indwelling lumbar catheter. <i>Alzheimer's Research and Therapy</i> , 2015, 7, 53.	6.2	22
110	Dickkopf-related protein 3 is a potential $A\beta$ -associated protein in Alzheimer's Disease. <i>Journal of Neurochemistry</i> , 2015, 134, 1152-1162.	3.9	31
111	CSF Neurofilament Light Chain but not FLT3 Ligand Discriminates Parkinsonian Disorders. <i>Frontiers in Neurology</i> , 2015, 6, 91.	2.4	60
112	A Practical Guide to Immunoassay Method Validation. <i>Frontiers in Neurology</i> , 2015, 6, 179.	2.4	348
113	The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases. <i>Frontiers in Neurology</i> , 2015, 6, 216.	2.4	36
114	P1-120: Standardization of a method for diagnostic biomarker validation for neurodegenerative diseases: App assays as example. , 2015, 11, P387-P387.		0
115	IC-P-089: Vascular and amyloid pathologies in memory clinic patients: Synergetic or independent?. , 2015, 11, P62-P62.		0
116	P4-100: Vascular and amyloid pathologies in memory clinic patients: Synergetic or independent?. , 2015, 11, P814-P814.		0
117	Susceptibility-Weighted Imaging Improves the Diagnostic Accuracy of 3T Brain MRI in the Work-Up of Parkinsonism. <i>American Journal of Neuroradiology</i> , 2015, 36, 454-460.	2.4	44
118	Ancillary investigations to diagnose parkinsonism: a prospective clinical study. <i>Journal of Neurology</i> , 2015, 262, 346-356.	3.6	34
119	Total glutamine synthetase levels in cerebrospinal fluid of Alzheimer's disease patients are unchanged. <i>Neurobiology of Aging</i> , 2015, 36, 1271-1273.	3.1	16
120	Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study. <i>Neurobiology of Aging</i> , 2015, 36, 2587-2596.	3.1	30
121	Amyloid beta-42 ($A\beta$ -42), neprilysin and cytokine levels. A pilot study in patients with HIV related cognitive impairments. <i>Journal of Neuroimmunology</i> , 2015, 282, 73-79.	2.3	12
122	Conventional 3T brain MRI and diffusion tensor imaging in the diagnostic workup of early stage parkinsonism. <i>Neuroradiology</i> , 2015, 57, 655-669.	2.2	38
123	Has CXCL13 an Added Value in Diagnosis of Neurosyphilis?. <i>Journal of Clinical Microbiology</i> , 2015, 53, 1693-1696.	3.9	35
124	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1924.	7.4	1,166
125	Fluid biomarkers in multiple system atrophy: A review of the MSA Biomarker Initiative. <i>Neurobiology of Disease</i> , 2015, 80, 29-41.	4.4	71
126	A multifunctional ELISA to measure oxidised proteins: oxPin1 in Alzheimer's brain as an example. <i>BBA Clinical</i> , 2015, 4, 1-6.	4.1	2

#	ARTICLE	IF	CITATIONS
127	Variability of CSF Alzheimer's Disease Biomarkers: Implications for Clinical Practice. PLoS ONE, 2014, 9, e100784.	2.5	72
128	Alzheimer Biomarkers and Clinical Alzheimer Disease were Not Associated with Increased Cerebrovascular Disease in a Memory Clinic Population. Current Alzheimer Research, 2014, 11, 40-46.	1.4	6
129	Aromatic L-Amino acid decarboxylase deficiency: A new case from Turkey with a novel mutation. Annals of Indian Academy of Neurology, 2014, 17, 234.	0.5	10
130	Scaffold cardiovirus and multiple sclerosis: no evidence for an association. Annals of Clinical and Translational Neurology, 2014, 1, 618-621.	3.7	6
131	Effect of 1 Night of Total Sleep Deprivation on Cerebrospinal Fluid β -Amyloid 42 in Healthy Middle-Aged Men. JAMA Neurology, 2014, 71, 971.	9.0	320
132	GLUT1 deficiency syndrome into adulthood: a follow-up study. Journal of Neurology, 2014, 261, 589-599.	3.6	67
133	CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controls. Parkinsonism and Related Disorders, 2014, 20, 112-115.	2.2	70
134	Structural biomarkers in the cerebrospinal fluid within 24h after a traumatic spinal cord injury: a descriptive analysis of 16 subjects. Spinal Cord, 2014, 52, 428-433.	1.9	74
135	Taking a closer look at Spag16 in multiple sclerosis. Journal of Neuroimmunology, 2014, 275, 14.	2.3	0
136	Decreased miR-219 expression in MS: Clinical implications?. Journal of Neuroimmunology, 2014, 275, 111.	2.3	0
137	Sperm-Associated Antigen 16 Is a Novel Target of the Humoral Autoimmune Response in Multiple Sclerosis. Journal of Immunology, 2014, 193, 2147-2156.	0.8	20
138	Addition of MHPG to Alzheimer's disease biomarkers improves differentiation of dementia with Lewy bodies from Alzheimer's disease but not other dementias. Alzheimer's and Dementia, 2014, 10, 448.	0.8	23
139	Serum angiogenin levels are elevated in ALS, but not Parkinson's disease: Table 1. Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1439-1440.	1.9	11
140	MicroRNAs in Alzheimer's disease: differential expression in hippocampus and cell-free cerebrospinal fluid. Neurobiology of Aging, 2014, 35, 152-158.	3.1	220
141	Cerebral Level of vGlut1 is Increased and Level of Glycine is Decreased in TgSwDI Mice. Journal of Alzheimer's Disease, 2014, 39, 89-101.	2.6	11
142	P1-124: BINDING OF THE AB43 PEPTIDE TO APOLIPOPROTEIN E AND ITS ROLE IN CLEARANCE. , 2014, 10, P346-P346.		0
143	P2-117: MICRO-RNAS AS NOVEL BIOMARKERS IN AD: DIFFERENTIAL EXPRESSION IN HIPPOCAMPUS AND IN CELL-FREE CEREBROSPINAL FLUID. , 2014, 10, P514-P514.		0
144	P2-051: THE HCMEC/D3 CELL LINE IS NOT SUITABLE AS A MODEL FOR β TRANSPORT BY THE HUMAN BLOOD-BRAIN BARRIER. , 2014, 10, P489-P489.		0

#	ARTICLE	IF	CITATIONS
145	P4-270: CORRELATIONS OF CSF BIOMARKER LEVELS WITH LATERAL VENTRICULAR CSF VOLUMES. , 2014, 10, P883-P883.		0
146	Serum Neuron-Specific Enolase Levels from the Same Patients Differ Between Laboratories: Assessment of a Prospective Post-cardiac Arrest Cohort. Neurocritical Care, 2013, 19, 161-166.	2.4	38
147	Reciprocal interactions between sleep, circadian rhythms and Alzheimer's disease: Focus on the role of hypocretin and melatonin. Ageing Research Reviews, 2013, 12, 188-200.	10.9	95
148	Impact of molecular imaging on the diagnostic process in a memory clinic. Alzheimer's and Dementia, 2013, 9, 414-421.	0.8	159
149	Levels of HVA, 5-HIAA, and MHPG in the CSF of vascular parkinsonism compared to Parkinson's disease and controls. Journal of Neurology, 2013, 260, 3129-3133.	3.6	10
150	Autoantibodies to cytosolic 5'-nucleotidase 1A in inclusion body myositis. Annals of Neurology, 2013, 73, 397-407.	5.3	206
151	Amyloid- β oligomer detection by ELISA in cerebrospinal fluid and brain tissue. Analytical Biochemistry, 2013, 433, 112-120.	2.4	103
152	CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimer's and Dementia, 2013, 9, 251-261.	0.8	344
153	A prediction model to calculate probability of Alzheimer's disease using cerebrospinal fluid biomarkers. Alzheimer's and Dementia, 2013, 9, 262-268.	0.8	22
154	Child Neurology: Differential diagnosis of a low CSF glucose in children and young adults. Neurology, 2013, 81, e178-81.	1.1	18
155	Cerebrospinal Fluid Analysis in the Workup of GLUT1 Deficiency Syndrome. JAMA Neurology, 2013, 70, 1440.	9.0	106
156	Anxiety is related to Alzheimer cerebrospinal fluid markers in subjects with mild cognitive impairment. Psychological Medicine, 2013, 43, 911-920.	4.5	93
157	Identification of coronin-1a as a novel antibody target for clinically isolated syndrome and multiple sclerosis. Journal of Neurochemistry, 2013, 126, 483-492.	3.9	13
158	Movement disorders in GLUT1 deficiency syndrome respond to the modified Atkins diet. Movement Disorders, 2013, 28, 1439-1442.	3.9	47
159	Replicated Evidence of Absence of Association between Serum S100B and (Risk of) Psychotic Disorder. PLoS ONE, 2013, 8, e82535.	2.5	11
160	The Diagnostic Value of CSF Amyloid- β 42 in Differentiation of Dementia Syndromes. Current Alzheimer Research, 2013, 10, 1034-1040.	1.4	10
161	TDP-43 plasma levels are higher in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 446-451.	2.1	66
162	Association between Hypocretin-1 and Amyloid- β 42 Cerebrospinal Fluid Levels in Alzheimer's Disease and Healthy Controls. Current Alzheimer Research, 2012, 9, 1119-1125.	1.4	55

#	ARTICLE	IF	CITATIONS
163	Age and diagnostic performance of Alzheimer disease CSF biomarkers. <i>Neurology</i> , 2012, 78, 468-476.	1.1	154
164	Linkage analysis for plasma amyloid beta levels in persons with hypertension implicates A β ²⁻⁴⁰ levels to presenilin 2. <i>Human Genetics</i> , 2012, 131, 1869-1876.	3.8	7
165	Diagnosis of progressive supranuclear palsy: can measurement of tau forms help?. <i>Neurobiology of Aging</i> , 2012, 33, 204.e17-204.e18.	3.1	11
166	CSF α -synuclein does not differentiate between parkinsonian disorders. <i>Neurobiology of Aging</i> , 2012, 33, 430.e1-430.e3.	3.1	89
167	Detection of tau forms in CSF requires sensitive techniques. <i>Neurobiology of Aging</i> , 2012, 33, 1841.	3.1	10
168	Hourly variability of cerebrospinal fluid biomarkers in Alzheimer's disease subjects and healthy older volunteers. <i>Neurobiology of Aging</i> , 2012, 33, 831.e1-831.e9.	3.1	36
169	Plasma β ² amyloid and the risk of Alzheimer's disease in Down syndrome. <i>Neurobiology of Aging</i> , 2012, 33, 1988-1994.	3.1	73
170	Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. <i>Biomarkers in Medicine</i> , 2012, 6, 419-430.	1.4	280
171	Novel cerebrospinal fluid and serum autoantibody targets for clinically isolated syndrome. <i>Journal of Neurochemistry</i> , 2012, 123, 568-577.	3.9	11
172	Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β ²⁴² . <i>Biomarkers in Medicine</i> , 2012, 6, 409-417.	1.4	76
173	Serum GFAP levels in optic neuropathies. <i>Journal of the Neurological Sciences</i> , 2012, 317, 117-122.	0.6	26
174	Methods for Analysis of Amyloid- β ² Aggregates. <i>Journal of Alzheimer's Disease</i> , 2012, 28, 735-758.	2.6	62
175	Reviewing reasons for the decreased CSF A β ⁴² concentration in Alzheimer. <i>Frontiers in Bioscience - Landmark</i> , 2012, 17, 2024.	3.0	41
176	Optimisation of the quantification of glutamine synthetase and myelin basic protein in cerebrospinal fluid by a combined acidification and neutralisation protocol. <i>Journal of Immunological Methods</i> , 2012, 381, 1-8.	1.4	4
177	Prognosis of coma after therapeutic hypothermia: A prospective cohort study. <i>Annals of Neurology</i> , 2012, 71, 206-212.	5.3	290
178	Human Prion Diseases in The Netherlands (1998-2009): Clinical, Genetic and Molecular Aspects. <i>PLoS ONE</i> , 2012, 7, e36333.	2.5	44
179	Cerebrospinal Fluid Glucose and Lactate: Age-Specific Reference Values and Implications for Clinical Practice. <i>PLoS ONE</i> , 2012, 7, e42745.	2.5	109
180	A rational design to create hybrid β ² -sheet breaker peptides to inhibit aggregation and toxicity of amyloid- β ² . <i>MedChemComm</i> , 2011, 2, 60-64.	3.4	10

#	ARTICLE	IF	CITATIONS
181	CSF α -synuclein concentrations do not fluctuate over hours and are not correlated to amyloid β in humans. <i>Neuroscience Letters</i> , 2011, 504, 336-338.	2.1	11
182	The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. <i>Alzheimer's and Dementia</i> , 2011, 7, 386.	0.8	354
183	CSF Tau, $A\beta$ 42, and MHPG Differentiate Dementia with Lewy Bodies from Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2011, 27, 377-384.	2.6	36
184	Inhibition of α -synuclein aggregation by small heat shock proteins. <i>Proteins: Structure, Function and Bioinformatics</i> , 2011, 79, 2956-2967.	2.6	104
185	The Paradox of Hyperdopaminuria in Aromatic L-Amino Acid Deficiency Explained. <i>JIMD Reports</i> , 2011, 4, 39-45.	1.5	11
186	Small Heat Shock Proteins Induce a Cerebral Inflammatory Reaction. <i>Journal of Neuroscience</i> , 2011, 31, 11992-12000.	3.6	36
187	Detection of elevated levels of α -synuclein oligomers in CSF from patients with Parkinson disease. <i>Neurology</i> , 2011, 77, 510-511.	1.1	16
188	Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy. <i>Neurology</i> , 2011, 76, 1443-1443.	1.1	9
189	Diagnostic challenges in parkinsonism. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 1099-1101.	2.8	4
190	Microglial Upregulation of Progranulin as a Marker of Motor Neuron Degeneration. <i>Journal of Neuropathology and Experimental Neurology</i> , 2010, 69, 1191-1200.	1.7	64
191	Do Amyloid β -associated Factors Co-deposit with $A\beta$ in Mouse Models for Alzheimer's Disease?. <i>Journal of Alzheimer's Disease</i> , 2010, 22, 345-355.	2.6	13
192	Cerebrospinal Fluid Tau and Amyloid β Proteins Do Not Correlate With Cognitive Functioning in Cognitively Impaired Memory Clinic Patients. <i>CNS Spectrums</i> , 2010, 15, 588-593.	1.2	4
193	Sulfation of heparan sulfate associated with amyloid- β plaques in patients with Alzheimer's disease. <i>Acta Neuropathologica</i> , 2010, 119, 211-220.	7.7	55
194	TDP-43 plasma levels do not differentiate sporadic inclusion body myositis from other inflammatory myopathies. <i>Acta Neuropathologica</i> , 2010, 120, 825-826.	7.7	9
195	Neurofilament ELISA validation. <i>Journal of Immunological Methods</i> , 2010, 352, 23-31.	1.4	86
196	Enoxaparin treatment administered at both early and late stages of amyloid β deposition improves cognition of APPswe/PS1dE9 mice with differential effects on brain $A\beta$ levels. <i>Neurobiology of Disease</i> , 2010, 40, 340-347.	4.4	65
197	Apolipoprotein E protects cultured pericytes and astrocytes from D- $A\beta$ 1-40-mediated cell death. <i>Brain Research</i> , 2010, 1315, 169-180.	2.2	45
198	A de novo p.Asp18Asn mutation in <i>TREX1</i> in a patient with Aicardi-Goutières syndrome. <i>American Journal of Medical Genetics, Part A</i> , 2010, 152A, 2612-2617.	1.2	35

#	ARTICLE	IF	CITATIONS
199	CEREBROSPINAL FLUID BIOMARKERS IN ALZHEIMER'S DISEASE: ARE THE HYPOTHESES MORE DYNAMIC THAN THE BIOMARKERS?. Journal of the American Geriatrics Society, 2010, 58, 1619-1620.	2.6	1
200	Glucose transporter-1 deficiency syndrome: the expanding clinical and genetic spectrum of a treatable disorder. Brain, 2010, 133, 655-670.	7.6	356
201	Tyrosine hydroxylase deficiency: a treatable disorder of brain catecholamine biosynthesis. Brain, 2010, 133, 1810-1822.	7.6	268
202	Cerebrospinal Fluid Biomarkers in Diagnosing Alzheimer's Disease in Clinical Practice: An Illustration with 3 Case Reports. Case Reports in Neurology, 2010, 2, 5-11.	0.7	3
203	Endotoxemia-induced inflammation and the effect on the human brain. Critical Care, 2010, 14, R81.	5.8	64
204	Aggregation and cytotoxic properties towards cultured cerebrovascular cells of Dutch-mutated A β ²⁴⁰ (DA β ²¹⁻⁴⁰) are modulated by sulfate moieties of heparin. Neuroscience Research, 2010, 66, 380-389.	1.9	24
205	The use of indexes in the interpretation of cerebrospinal fluid analyses. Neurobiology of Aging, 2010, 31, 1654.	3.1	0
206	CSF τ -Synuclein Does Not Discriminate Dementia with Lewy Bodies from Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 22, 87-95.	2.6	87
207	CSF Neurofilament Proteins Levels are Elevated in Sporadic Creutzfeldt-Jakob Disease. Journal of Alzheimer's Disease, 2010, 21, 569-576.	2.6	38
208	CSF Studies Facilitate DNA Diagnosis in Familial Alzheimer's Disease Due to a Presenilin-1 Mutation. Journal of Alzheimer's Disease, 2009, 17, 53-57.	2.6	7
209	Cerebrospinal Fluid τ -Synuclein Does Not Discriminate Between Dementia Disorders. Journal of Alzheimer's Disease, 2009, 16, 363-369.	2.6	87
210	Amyloid β induces cellular relocalization and production of agrin and glypican-1. Brain Research, 2009, 1260, 38-46.	2.2	13
211	Cerebrospinal fluid amyloid β ₄₀ is decreased in cerebral amyloid angiopathy. Annals of Neurology, 2009, 66, 245-249.	5.3	171
212	Increased plasma amyloid- β ²⁴² protein in sporadic inclusion body myositis. Acta Neuropathologica, 2009, 118, 429-431.	7.7	18
213	CSF neurofilament protein analysis in the differential diagnosis of ALS. Journal of Neurology, 2009, 256, 615-619.	3.6	72
214	LRP1 shedding in human brain: roles of ADAM10 and ADAM17. Molecular Neurodegeneration, 2009, 4, 17.	10.8	88
215	Small heat shock proteins associated with cerebral amyloid angiopathy of hereditary cerebral hemorrhage with amyloidosis (Dutch type) induce interleukin-6 secretion. Neurobiology of Aging, 2009, 30, 229-240.	3.1	39
216	Neuropeptide changes and neuroactive amino acids in CSF from humans and sheep with neuronal ceroid lipofuscinoses (NCLs, Batten disease). Neurochemistry International, 2009, 55, 783-788.	3.8	14

#	ARTICLE	IF	CITATIONS
217	CSF hypocretin-1 levels are normal in patients with amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2009, 10, 487-489.	2.1	10
218	CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment. <i>JAMA - Journal of the American Medical Association</i> , 2009, 302, 385.	7.4	1,009
219	Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. <i>Lancet Neurology</i> , The, 2009, 8, 619-627.	10.2	542
220	The accuracy of the arginine growth hormone test in Parkinsonism. <i>Movement Disorders</i> , 2008, 23, 1330-1330.	3.9	0
221	Immunocapture-based fluorometric assay for the measurement of neprilysin-specific enzyme activity in brain tissue homogenates and cerebrospinal fluid. <i>Journal of Neuroscience Methods</i> , 2008, 167, 229-236.	2.5	41
222	A more efficient enzyme-linked immunosorbent assay for measurement of β -synuclein in cerebrospinal fluid. <i>Journal of Neuroscience Methods</i> , 2008, 168, 182-185.	2.5	32
223	Rituximab and Intravenous Immunoglobulins for Relapsing Postinfectious Opsoclonus-Myoclonus Syndrome. <i>Pediatric Neurology</i> , 2008, 39, 213-217.	2.1	28
224	Two Greek siblings with sepiapterin reductase deficiency. <i>Molecular Genetics and Metabolism</i> , 2008, 94, 403-409.	1.1	23
225	Cerebrospinal Fluid Biomarkers in the Evaluation of Alzheimer Disease. <i>Clinical Chemistry</i> , 2008, 54, 1589-1591.	3.2	5
226	No Effect of One-Year Treatment with Indomethacin on Alzheimer's Disease Progression: A Randomized Controlled Trial. <i>PLoS ONE</i> , 2008, 3, e1475.	2.5	123
227	Amyloid Beta Protein and Tau in Cerebrospinal Fluid and Plasma as Biomarkers for Dementia: A Review of Recent Literature. <i>Current Clinical Pharmacology</i> , 2008, 3, 123-131.	0.6	68
228	POTENTIAL PITFALLS IN THE ANALYSIS OF CSF BIOMARKERS IN ALZHEIMER'S DISEASE AND VASCULAR DEMENTIA. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2007, 62, 924-925.	3.6	1
229	Diagnostic Accuracy of ELISA and xMAP Technology for Analysis of Amyloid β 242 and Tau Proteins. <i>Clinical Chemistry</i> , 2007, 53, 859-865.	3.2	62
230	Current state and future directions of neurochemical biomarkers for Alzheimer's disease. <i>Clinical Chemistry and Laboratory Medicine</i> , 2007, 45, 1421-34.	2.3	76
231	CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease. <i>Neurobiology of Aging</i> , 2007, 28, 742-747.	3.1	121
232	Lipoprotein Receptor-Related Protein-1 Mediates Amyloid- β 2-Mediated Cell Death of Cerebrovascular Cells. <i>American Journal of Pathology</i> , 2007, 171, 1989-1999.	3.8	120
233	Mutations in the cyclic adenosine monophosphate response element of the tyrosine hydroxylase gene. <i>Annals of Neurology</i> , 2007, 62, 422-426.	5.3	29
234	Heat Shock Proteins and Amateur Chaperones in Amyloid-Beta Accumulation and Clearance in Alzheimer's Disease. <i>Molecular Neurobiology</i> , 2007, 35, 203-216.	4.0	105

#	ARTICLE	IF	CITATIONS
235	CXCL16 is elevated in the cerebrospinal fluid versus serum and in inflammatory conditions with suspected and proved central nervous system involvement. <i>Neuroscience Letters</i> , 2006, 397, 145-148.	2.1	44
236	Chronic Herpes Simplex Virus Encephalitis in Childhood. <i>Pediatric Neurology</i> , 2006, 35, 57-61.	2.1	4
237	Cerebrospinal Fluid Amyloid ss42/Phosphorylated Tau Ratio Discriminates Between Alzheimer's Disease and Vascular Dementia. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2006, 61, 755-758.	3.6	89
238	Small heat shock protein HspB8: its distribution in Alzheimer's disease brains and its inhibition of amyloid- β protein aggregation and cerebrovascular amyloid- β toxicity. <i>Acta Neuropathologica</i> , 2006, 111, 139-149.	7.7	125
239	CSF protein profiling using Multiplex Immuno-assay. <i>Journal of Neurology</i> , 2006, 253, 1177-1184.	3.6	18
240	Small heat shock proteins inhibit amyloid- β protein aggregation and cerebrovascular amyloid- β protein toxicity. <i>Brain Research</i> , 2006, 1089, 67-78.	2.2	193
241	Multiple Diagnostic Tests Are Needed to Assess Multiple Causes of Dementia. <i>Archives of Neurology</i> , 2006, 63, 144.	4.5	14
242	Cerebrospinal fluid tau levels in frontotemporal dementia. <i>Annals of Neurology</i> , 2005, 58, 656-657.	5.3	9
243	Expression pattern of apoptosis-related markers in Huntington's disease. <i>Acta Neuropathologica</i> , 2005, 109, 321-328.	7.7	87
244	MALDI-TOF Mass Spectrometry Analysis of Cerebrospinal Fluid Tryptic Peptide Profiles to Diagnose Leptomeningeal Metastases in Patients with Breast Cancer. <i>Molecular and Cellular Proteomics</i> , 2005, 4, 1341-1349.	3.8	76
245	Apolipoprotein E Genotype Regulates Amyloid- β Cytotoxicity. <i>Journal of Neuroscience</i> , 2005, 25, 3621-3627.	3.6	52
246	Cerebral Amyloid Angiopathy with Severe Secondary Vascular Pathology: A Histopathological Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2005, 20, 321-330.	1.5	7
247	The sex difference of plasma homovanillic acid is unaffected by cross-sex hormone administration in transsexual subjects. <i>Journal of Endocrinology</i> , 2005, 187, 109-116.	2.6	6
248	Cerebral Microvascular Amyloid β Protein Deposition Induces Vascular Degeneration and Neuroinflammation in Transgenic Mice Expressing Human Vasculotropic Mutant Amyloid β Precursor Protein. <i>American Journal of Pathology</i> , 2005, 167, 505-515.	3.8	177
249	Creatine protects against 3-nitropropionic acid-induced cell death in murine corticostriatal slice cultures. <i>Brain Research</i> , 2004, 1024, 16-24.	2.2	12
250	Cerebrospinal fluid A β 42 levels in multiple system atrophy. <i>Movement Disorders</i> , 2004, 19, 238-240.	3.9	32
251	Cerebrospinal fluid analysis differentiates multiple system atrophy from Parkinson's disease. <i>Movement Disorders</i> , 2004, 19, 571-579.	3.9	87
252	P3-045 Tau protein phosphorylated at threonine 181 in cerebrospinal fluid as a possible biomarker for Alzheimer's disease. <i>Neurobiology of Aging</i> , 2004, 25, S364.	3.1	2

#	ARTICLE	IF	CITATIONS
253	P3-167 Specific association of small heat shock proteins with the pathological features of Alzheimer's and Parkinson's disease brains. <i>Neurobiology of Aging</i> , 2004, 25, S403.	3.1	0
254	Analytical performance of a kinetic method for the determination of lactate dehydrogenase catalytic concentration in cerebrospinal fluid. <i>Clinica Chimica Acta</i> , 2004, 346, 221-223.	1.1	2
255	Insulin inhibits amyloid β -induced cell death in cultured human brain pericytes. <i>Neurobiology of Aging</i> , 2004, 25, 93-103.	3.1	64
256	P1-178 Small heat shock proteins affect amyloid- β protein aggregation and inhibit cerebrovascular amyloid- β protein toxicity. <i>Neurobiology of Aging</i> , 2004, 25, S146.	3.1	0
257	Absence of heparan sulfate proteoglycans in Lewy bodies and Lewy neurites in Parkinson's disease brains. <i>Journal of Alzheimer's Disease</i> , 2004, 6, 469-474.	2.6	10
258	Heparan sulphate proteoglycans in Alzheimer's disease and amyloid- β related disorders. <i>Lancet Neurology</i> , The, 2003, 2, 482-492.	10.2	192
259	Pathogenesis of cerebral amyloid angiopathy. <i>Brain Research Reviews</i> , 2003, 43, 207-223.	9.0	142
260	Quality Assurance for Cerebrospinal Fluid Protein Analysis: International Consensus by an Internet-Based Group Discussion. <i>Clinical Chemistry and Laboratory Medicine</i> , 2003, 41, 331-7.	2.3	62
261	Accumulation of the Amyloid- β Precursor Protein in Multivesicular Body-like Organelles. <i>Journal of Histochemistry and Cytochemistry</i> , 2002, 50, 681-690.	2.5	30
262	Measurement of glial fibrillary acidic protein in blood: an analytical method. <i>Clinica Chimica Acta</i> , 2002, 326, 151-154.	1.1	62
263	Accumulation of heparan sulfate proteoglycans in cerebellar senile plaques. <i>Neurobiology of Aging</i> , 2002, 23, 537-545.	3.1	64
264	3-Nitropropionic acid induces cell death and mitochondrial dysfunction in rat corticostriatal slice cultures. <i>Neuroscience Letters</i> , 2002, 329, 86-90.	2.1	18
265	Comparison of Methods for the Detection of Oligoclonal IgG Bands in Cerebrospinal Fluid and Serum: Results of the Dutch Quality Control Survey. <i>Clinical Chemistry</i> , 2002, 48, 1578-1580.	3.2	16
266	Inhibition of amyloid- β -induced cell death in human brain pericytes in vitro. <i>Brain Research</i> , 2002, 952, 111-121.	2.2	24
267	Expression of the cytokine leukemia inhibitory factor and pro-apoptotic insulin-like growth factor binding protein-3 in Alzheimer's disease. <i>Acta Neuropathologica</i> , 2002, 104, 525-533.	7.7	40
268	Collagen XVIII: a Novel Heparan Sulfate Proteoglycan Associated with Vascular Amyloid Depositions and Senile Plaques in Alzheimer's Disease Brains. <i>Brain Pathology</i> , 2002, 12, 456-462.	4.1	69
269	Heparan sulfate proteoglycan expression in cerebrovascular amyloid β deposits in Alzheimer's disease and hereditary cerebral hemorrhage with amyloidosis (Dutch) brains. <i>Acta Neuropathologica</i> , 2001, 102, 604-614.	7.7	93
270	Hypoglycorrhachia: A simple clue, simply missed. <i>Annals of Neurology</i> , 2001, 49, 685-686.	5.3	11

#	ARTICLE	IF	CITATIONS
271	Hypoglycorrhachia: A simple clue, simply missed. <i>Annals of Neurology</i> , 2001, 49, 685-686.	5.3	1
272	Amyloid-beta-induced Degeneration of Human Brain Pericytes Is Dependent on the Apolipoprotein E Genotype. <i>Annals of the New York Academy of Sciences</i> , 2000, 903, 187-199.	3.8	43
273	Degeneration of Human Cerebrovascular Smooth Muscle Cells and Pericytes Caused by Amyloid β^2 Protein. , 2000, , 265-279.		4
274	Agria Is a Major Heparan Sulfate Proteoglycan Accumulating in Alzheimer's Disease Brain. <i>American Journal of Pathology</i> , 1999, 155, 2115-2125.	3.8	123
275	Amyloid Formation in Senile Plaques and Congophilic Angiopathy. <i>Journal of Neuropathology and Experimental Neurology</i> , 1998, 57, 97-98.	1.7	0
276	Differences between the Pathogenesis of Senile Plaques and Congophilic Angiopathy in Alzheimer Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 1997, 56, 751-761.	1.7	57
277	Rapid Degeneration of Cultured Human Brain Pericytes by Amyloid β^2 Protein. <i>Journal of Neurochemistry</i> , 1997, 68, 1135-1141.	3.9	144
278	Transient Induction of E-Selectin Expression Following TNF α -Based Isolated Limb Perfusion in Melanoma and Sarcoma Patients Is Not Tumor Specific. <i>Journal of Immunotherapy</i> , 1996, 19, 33-44.	2.4	15